Head to Head Survey: Profound Medical (NASDAQ:PROF) and Curaleaf (OTCMKTS:CURLF)

Profound Medical (NASDAQ:PROF – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares Profound Medical and Curaleaf’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Profound Medical -137.51% -59.57% -47.87%
Curaleaf -0.76% 0.43% 0.13%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Profound Medical and Curaleaf, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profound Medical 1 0 1 1 2.67
Curaleaf 0 1 2 1 3.00

Profound Medical presently has a consensus price target of $11.50, indicating a potential upside of 66.43%. Curaleaf has a consensus price target of $6.00, indicating a potential downside of 22.68%. Given Profound Medical’s higher probable upside, equities analysts plainly believe Profound Medical is more favorable than Curaleaf.

Volatility and Risk

Profound Medical has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Institutional and Insider Ownership

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 0.0% of Curaleaf shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Profound Medical and Curaleaf”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Profound Medical $23.63 million 10.71 -$42.57 million ($0.93) -7.43
Curaleaf $1.27 billion 1.43 -$231.07 million ($0.04) -194.00

Profound Medical has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Curaleaf beats Profound Medical on 8 of the 14 factors compared between the two stocks.

About Profound Medical

(Get Free Report)

Profound Medical Corp. is a Canadian medical-device company that develops MRI-guided therapies using focused ultrasound. Its systems combine magnetic resonance imaging with ultrasound energy to help clinicians target and treat tissue without conventional open surgery. The company’s TULSA-PRO system is designed to ablate prostate tissue. It also offers Sonalleve, an MRI-guided focused-ultrasound platform developed for applications including the treatment of uterine fibroids and the palliation of pain from bone metastases.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc. is a cannabis company that cultivates, processes and sells cannabis products for medical and adult-use markets. Its products include cannabis flower, pre-rolls, concentrates, vapes, edibles, tinctures and topical products, sold under brands including Curaleaf, Select and Grassroots. The company operates across multiple U.S. markets through cultivation and processing facilities, wholesale operations and retail dispensaries. Through Curaleaf International, it also serves medical cannabis markets in Europe and other international markets.

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.